PET mapping of receptor occupancy using joint direct parametric reconstruction.

Autor: Marin T, Belov V, Chemli Y, Ouyang J, Najmaoui Y, Fakhri GE, Duvvuri S, Iredale P, Guehl NJ, Normandin MD, Petibon Y

Publikováno v: IEEE transactions on bio-medical engineering [IEEE Trans Biomed Eng] 2024 Oct 24; Vol. PP. Date of Electronic Publication: 2024 Oct 24.

PET imaging of M4 muscarinic acetylcholine receptors in rhesus macaques using [ ¹¹ C]MK-6884: Quantification with kinetic modeling and receptor occupancy by CVL-231 (emraclidine), a novel positive allosteric modulator.

Autor: Belov V; Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Guehl NJ; Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Duvvuri S; Cerevel Therapeutics, LLC, Cambridge, MA, USA., Iredale P; Cerevel Therapeutics, LLC, Cambridge, MA, USA., Moon SH; Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Dhaynaut M; Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Chakilam S; Cerevel Therapeutics, LLC, Cambridge, MA, USA., MacDonagh AC; Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Rice PA; Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Yokell DL; Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Renger JJ; Cerevel Therapeutics, LLC, Cambridge, MA, USA., El Fakhri G; Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Normandin MD; Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Publikováno v: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism [J Cereb Blood Flow Metab] 2024 Aug; Vol. 44 (8), pp. 1329-1342. Date of Electronic Publication: 2024 Mar 13.

Setting the TEMPO: A phase 3 program to investigate tavapadon, a selective D1/D5 partial agonist, for Parkinson’s disease

Autor: Fernandez, H.F., Pfister, S.P., Leoni, M., Berry, M., Gangadharan, A., Duvvuri, S., Parker, J., Wang, S., Briscoe, R.B., Sanchez, R.

Publikováno v: In Parkinsonism and Related Disorders August 2023 113 Supplement

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Dopamine agonists in Parkinson's disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment.

Autor: Isaacson SH; Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, USA., Hauser RA; Parkinson's Disease and Movement Disorders Center, Parkinson Foundation Center of Excellence, University of South Florida, Tampa, FL, USA., Pahwa R; Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center, Kansas City, KS, USA., Gray D; Vigil Neuroscience, Inc, Watertown, MA, USA., Duvvuri S; Cerevel Therapeutics, Boston, MA, USA.

Publikováno v: Clinical parkinsonism & related disorders [Clin Park Relat Disord] 2023 Jul 07; Vol. 9, pp. 100212. Date of Electronic Publication: 2023 Jul 07 (Print Publication: 2023).